An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice

Nicolas Martinez-Calle; Amy A Kirkwood; Maxine Lamb; Alexandra Gwen Smith; Kate Manos; Caroline Shrubsole; N Gray; Sapna Ladani; K Lewis; Mark Bishton; Matthew J Ahearne; Eliza Hawkes; Wendy Osborne; G Colins; C. Burton; Christopher P Fox

doi:10.1111/bjh.16638

An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice

Nicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, Alexandra Gwen Smith, Kate Manos, Caroline Shrubsole, N Gray, Sapna Ladani, K Lewis, Mark Bishton, Matthew J Ahearne, Eliza Hawkes, Wendy Osborne, G Colins, C. Burton, Christopher P Fox

Health Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Standard first-line (1L) therapy for systemic ALCL (sALCL) is CHOP-based chemotherapy, with or without consolidative autologous stem cell transplant (ASCT) (Schmitz, Blood, 2010). Approximately 40–65% of patients experience relapsed/refractory disease, for which brentuximab vedotin (BV) as monotherapy has established efficacy (Pro, Blood, 2017)

BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L.

Original language	English
Article number	BSH2020-PO-091
Journal	British Journal of Haematology
Volume	189
Issue number	S1
DOIs	https://doi.org/10.1111/bjh.16638
Publication status	Published - 27 Apr 2020
Event	60th Annual Scientific Meeting of the British Society for Haematology - Birmingham, United Kingdom Duration: 27 Apr 2020 → 29 Apr 2020 Conference number: 60

Access to Document

10.1111/bjh.16638

Cite this

Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A. G., Manos, K., Shrubsole, C., Gray, N., Ladani, S., Lewis, K., Bishton, M., Ahearne, M. J., Hawkes, E., Osborne, W., Colins, G., Burton, C., & Fox, C. P. (2020). An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice. British Journal of Haematology, 189(S1), Article BSH2020-PO-091. https://doi.org/10.1111/bjh.16638

@article{43484815ae7d4ec5bf001813ce7d5c0c,

title = "An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice",

abstract = "Standard first-line (1L) therapy for systemic ALCL (sALCL) is CHOP-based chemotherapy, with or without consolidative autologous stem cell transplant (ASCT) (Schmitz, Blood, 2010). Approximately 40–65% of patients experience relapsed/refractory disease, for which brentuximab vedotin (BV) as monotherapy has established efficacy (Pro, Blood, 2017)BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L. ",

author = "Nicolas Martinez-Calle and Kirkwood, {Amy A} and Maxine Lamb and Smith, {Alexandra Gwen} and Kate Manos and Caroline Shrubsole and N Gray and Sapna Ladani and K Lewis and Mark Bishton and Ahearne, {Matthew J} and Eliza Hawkes and Wendy Osborne and G Colins and C. Burton and Fox, {Christopher P}",

year = "2020",

month = apr,

day = "27",

doi = "10.1111/bjh.16638",

language = "English",

volume = "189",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "S1",

note = "60th Annual Scientific Meeting of the British Society for Haematology ; Conference date: 27-04-2020 Through 29-04-2020",

}

Martinez-Calle, N, Kirkwood, AA, Lamb, M , Smith, AG, Manos, K, Shrubsole, C, Gray, N, Ladani, S, Lewis, K, Bishton, M, Ahearne, MJ, Hawkes, E, Osborne, W, Colins, G, Burton, C & Fox, CP 2020, 'An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice', British Journal of Haematology, vol. 189, no. S1, BSH2020-PO-091. https://doi.org/10.1111/bjh.16638

An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice. / Martinez-Calle, Nicolas; Kirkwood, Amy A; Lamb, Maxine et al.
In: British Journal of Haematology, Vol. 189, No. S1, BSH2020-PO-091, 27.04.2020.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - An international multicentre study of consecutively diagnosed patients with ALCL

T2 - 60th Annual Scientific Meeting of the British Society for Haematology

AU - Martinez-Calle, Nicolas

AU - Kirkwood, Amy A

AU - Lamb, Maxine

AU - Smith, Alexandra Gwen

AU - Manos, Kate

AU - Shrubsole, Caroline

AU - Gray, N

AU - Ladani, Sapna

AU - Lewis, K

AU - Bishton, Mark

AU - Ahearne, Matthew J

AU - Hawkes, Eliza

AU - Osborne, Wendy

AU - Colins, G

AU - Burton, C.

AU - Fox, Christopher P

N1 - Conference code: 60

PY - 2020/4/27

Y1 - 2020/4/27

N2 - Standard first-line (1L) therapy for systemic ALCL (sALCL) is CHOP-based chemotherapy, with or without consolidative autologous stem cell transplant (ASCT) (Schmitz, Blood, 2010). Approximately 40–65% of patients experience relapsed/refractory disease, for which brentuximab vedotin (BV) as monotherapy has established efficacy (Pro, Blood, 2017)BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L.

AB - Standard first-line (1L) therapy for systemic ALCL (sALCL) is CHOP-based chemotherapy, with or without consolidative autologous stem cell transplant (ASCT) (Schmitz, Blood, 2010). Approximately 40–65% of patients experience relapsed/refractory disease, for which brentuximab vedotin (BV) as monotherapy has established efficacy (Pro, Blood, 2017)BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L.

U2 - 10.1111/bjh.16638

DO - 10.1111/bjh.16638

M3 - Meeting abstract

SN - 0007-1048

VL - 189

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - S1

M1 - BSH2020-PO-091

Y2 - 27 April 2020 through 29 April 2020

ER -